Setting 
My Cart

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Toggle Nav
mobile icon
Close
  • Menu
  • Setting
  • Home
  • Search results for: 'research area pi3k akt signaling akt'

Search results for: 'research area pi3k akt signaling akt'

Items 91-99 of 99

Page
per page
  1. GDC-0449 (Vismodegib)
    A3021 GDC-0449 (Vismodegib)
     1 Citation
    Target: P-glycoprotein (P-gp)|Hedgehog
    Summary: Hedgehog antagonist,potent and selective
      ≥21.08 mg/mL
  2. NU 7026
    A8649 NU 7026
    Target: PI3K|DNA-PK|ATM
    Summary: DNPK inhibitor,ATP-competitive and potent
      insoluble in EtOH; insoluble in DMSO; insoluble in H2O
  3. WYE-125132 (WYE-132)
    B1642 WYE-125132 (WYE-132)
    Target: mTOR
    Summary: ATP-competitive mTOR inhibitor, highly potent
      insoluble in EtOH; insoluble in H2O; ≥13 mg/mL
  4. NU7441 (KU-57788)
    A8315 NU7441 (KU-57788)
     4 Citation
    Target: PI3K|DNA-PK
    Summary: DNA-PK inhibitor
      insoluble in EtOH; insoluble in H2O; ≥4.13 mg/mL
  5. Tofacitinib (CP-690550) Citrate
    A4135 Tofacitinib (CP-690550) Citrate
     2 Citation
    Target: JAK
    Summary: Potent JAK inhibitor
      ≥25.22 mg/mL
  6. Afatinib (BIBW2992)
    A8247 Afatinib (BIBW2992)
     1 Citation
    Target: EGFR
    Summary: Irreversible EGFR/HER2 inhibitor
      ≥24.3 mg/mL
  7. Nintedanib (BIBF 1120)
    A8252 Nintedanib (BIBF 1120)
     3 Citation
    Target: VEGFR|PDGFR|FGFR
    Summary: VEGFR/PDGFR/FGFR inhibitor
      insoluble in H2O; insoluble in EtOH; ≥5.34 mg/mL
  8. R406
    A8546 R406
     1 Citation
    Target: Syk
    Summary: SYK inhibitor,potent and ATP-competitive
      ≥31.45 mg/mL
  9. BDNF, human recombinant
    P1007 BDNF, human recombinant
    Target: Trk Receptors

Items 91-99 of 99

Page
per page
Shop By
Now Shopping by
  1. Specificity Selective Remove This Item
Clear All
Shopping Options
Category
  1. Signaling Pathways 97item
  2. Peptides 1 item
  3. Peptides & Proteins 1 item
Reversibility
  1. Reversible 4item
  2. Irreversible 1 item
Target
  1. Histone Deacetylases (HDACs) 1 item
  2. Akt 5item
  3. PI3K 22item
  4. Raf 6item
  5. mTOR 10item
  6. Androgen Receptors 1 item
  7. GSK-3 5item
  8. P-glycoprotein (P-gp) 1 item
  9. PLK 1 item
  10. VEGFR 3item
  11. PDGFR 1 item
  12. Phosphodiesterases (PDEs) 1 item
  13. p38 4item
  14. PKB 1 item
  15. JNK 4item
  16. MEK 5item
  17. PORCN 1 item
  18. FGFR 1 item
  19. GABAB Receptors 1 item
  20. Smoothened 1 item
  21. Trk Receptors 1 item
  22. STAT 4item
  23. EGFR 2item
  24. Hedgehog 1 item
  25. BMP and Other Activin Receptors 2item
  26. JAK 2item
  27. Syk 1 item
  28. DNA-PK 4item
  29. HSP90 1 item
  30. TNKS 1 item
  31. Toll-like receptors (TLRs) 1 item
  32. ERK 1 item
  33. PKC 3item
  34. Melanocortin (MC) Receptors 1 item
  35. Fatty-acid-binding proteins (FABPs) 1 item
  36. NO Donors / Precursors 1 item
  37. IL Receptors 1 item
  38. PKD 1 item
  39. ATM 1 item
Reported Experiments
  1. Animal Experiments 90item
  2. Cell Experiments 56item
Related Disease
  1. Acute Myelogenous Leukemia 1 item
  2. Acute Myeloid Leukemia 2item
  3. Bladder Cancer 1 item
  4. Breast Cancer 23item
  5. Cancer 64item
  6. Cervical Cancer 2item
  7. Cholangiocarcinoma 1 item
  8. Chronic Lymphocytic Leukemia 1 item
  9. Colon Cancer 10item
  10. Colon Carcinoma 1 item
  11. Colorectal Cancer 11item
  12. Glioblastoma 10item
  13. Glioma 4item
  14. Hepatocellular Carcinoma 1 item
  15. Leukemia 5item
  16. Liver Cancer 1 item
  17. Lung Cancer 7item
  18. Lymphoma 2item
  19. Melanoma 6item
  20. Multiple Myeloma 1 item
  21. Myeloma 1 item
  22. Neuroblastoma 2item
  23. Non-small Cell Lung Cancer 6item
  24. Ovarian Cancer 7item
  25. Pancreatic Cancer 9item
  26. Pancreatic Carcinoma 2item
  27. Prostate Cancer 11item
  28. Pulmonary Arterial Hypertension 1 item
  29. Pulmonary Fibrosis 1 item
  30. Renal Cancer 2item
  31. Rheumatoid Arthritis 2item
  32. Thyroid Cancer 2item
  33. Type 2 Diabetes 2item